Article

Myopic keratophakia considered alternative for correction of high myopia

San Francisco-Correction of high myopia with a phakic IOL or by clear lens exchange does pose some risk for patients because these methods are intraocular procedures. To avoid the associated risks of IOL surgery-such as infection, cataract formation in the case of phakic lenses, possible endothelial damage, pupil ovalization, zonular problems, and retinal problems, surgeons might want to consider myopic keratophakia and excimer laser ablation instead, explained Luis Antonio Ruiz, MD.

Dr. Ruiz, a cataract and refractive surgeon from Bogota, Colombia, showed a video demonstrating this technique in a patient with high myopia and then shared the long-term results of 13 patients who underwent this procedure, during the Innovator's Session at the American Society of Cataract and Refractive Surgery annual meeting.

Dr. Ruiz presented the results of 21 eyes of 13 patients with a mean age of 33 years (range, 17 to 42) who underwent the procedure.

The mean preoperative sphere was –13.55 D (range, –0.75 to –23 D). There were three cases of low myopia but high astigmatism.

The mean cylinder was –8.5 D. The preoperative spherical equivalent (SE) was –15.36 D (range, –4.26 to –23.5 D). The average follow-up was 4.4 years (range, 1 to 7 years).

After myopic keratophakia, the postoperative mean sphere improved to –0.63 D and the postoperative mean cylinder was –0.81 D. The mean SE went down to –0.99 D.

Uncorrected visual acuity (UCVA) improved from 20/400 on average preoperatively to a mean of 20/40. Best-corrected visual acuity also increased slightly in these 21 eyes, explained Dr. Ruiz.

When Dr. Ruiz compared the best spectacle-corrected visual acuity (BSCVA) preoperatively to the UCVA postoperatively, in many cases the postoperative UCVA was better than the preoperative BSCVA.

Dr. Ruiz also showed some examples of corneal topography before and after myopic keratophakia was performed.

"We can change asphericity of the cornea to reduce spherical aberrations with high degrees of correction," he said.

The advantages of myopic keratophakia include safety, a large optical zone and transition zone, and improved UCVA. Nine eyes underwent enhancements, which were easy to perform, and contrast sensitivity improved in most cases.

"Now we have a really good option for treatment of high myopia," Dr. Ruiz concluded.

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Related Videos
Shehzad Batliwala, DO, aka Dr. Shehz, discussed humanitarian ophthalmology and performing refractive surgery in low-resource, high-risk areas at the ASCRS Foundation Symposium.
(Image credit: Ophthalmology Times) ASCRS 2025: Advancing vitreous care with Inder Paul Singh, MD
(Image credit: Ophthalmology Times) The Residency Report: Study provides new insights into USH2A target end points
Lisa Nijm, MD, says preoperative osmolarity testing can manage patient expectations and improve surgical results at the 2025 ASCRS annual meeting
At the 2025 ASCRS Annual Meeting, Weijie Violet Lin, MD, ABO, shares highlights from a 5-year review of cross-linking complications
Maanasa Indaram, MD, is the medical director of the pediatric ophthalmology and adult strabismus division at University of California San Francisco, and spoke about corneal crosslinking (CXL) at the 2025 ASCRS annual meeting
(Image credit: Ophthalmology Times) ASCRS 2025: Taylor Strange, DO, assesses early visual outcomes with femto-created arcuate incisions in premium IOL cases
(Image credit: Ophthalmology Times) ASCRS 2025: Neda Shamie, MD, shares her early clinical experience with the Unity VCS system
Patricia Buehler, MD, MPH, founder and CEO of Osheru, talks about the Ziplyft device for noninvasive blepharoplasty at the 2025 American Society of Cataract and Refractive Surgeons (ASCRS) annual meeting
(Image credit: Ophthalmology Times) ASCRS 2025: Bonnie An Henderson, MD, on leveraging artificial intelligence in cataract refractive surgery
© 2025 MJH Life Sciences

All rights reserved.